OHF GOES BANKRUPT DUE TO CLONATEC

26 June 1994

OHF, the French holding group which rescued companies and sold them off profitably, has itself gone under and filed for bankruptcy. The Nanterrre commercial tribunal is expected to name a receiver shortly.

Some companies taken over by OHF have been sold off, but problems affected Clonatec, a small manufacturer of diagnostic tests on which OHF hoped to concentrate. French drug major Sanofi attacked Clonatec over several AIDS tests and the French drug regulatory agency compelled the company to withdraw one of its AIDS tests on safety grounds.

The German chemicals/pharmaceuticals group Hoechst also ended an agreement with Clonatec, and potential investors faded away. OHF chairman Philippe Brule says he is disappointed no deal could be struck with Sanofi. At the end of last year, OHF completed what it hoped would have been a rescue package under the direction of the Interministerial Committee for Industrial Reconstruction.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight